2',3'-Dideoxyadenosine 5'-triphosphate (lithium salt)
(Synonyms: ddATP) 目录号 : GC52501An inhibitor of reverse transcriptases and DNA polymerases
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2',3'-Dideoxyadenosine 5'-triphosphate (ddATP) is an in vitro inhibitor of reverse transcriptases from retroviruses, including HIV-1 and visna (Kis = 20 and 37 nM, respectively).1,2,3 It also blocks, in vitro, mammalian and bacterial DNA polymerases.4,5 ddATP, produced intracellularly by the phosphorylation of exogenously supplied 2',3'-dideoxyadenosine, competes with dATP, resulting in chain termination.4,5 Because of this activity, dideoxynucleoside 5'-triphosphates, including ddATP, are used to terminate chain extension produced by the Taq polymerase used in polymerase chain reactions.6 It is also an antagonist of the purinergic receptor P2X2/3 (pIC50 = 6.5).7
1.Boyle, N.A., Rajwanshi, V.K., Prhavc, M., et al.Synthesis of 2',3'-dideoxynucleoside 5'-α-P-borano-β,γ-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcriptaseJ. Med. Chem.48(7)2695-2700(2005) 2.Frank, K.B., McKernan, P.A., Smith, R.A., et al.Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosidesAntimicrob. Agents Chemother.31(9)1369-1374(1987) 3.Ueno, T., Shirasaka, T., and Mitsuya, H.Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphatesJ. Biol. Chem.270(40)23605-23611(1995) 4.Toji, L., and Cohen, S.S.The enzymatic termination of polydeoxynucleotides by 2',3'-dideoxyadenosine triphosphateProc. Natl. Acad. Sci. USA63(3)871-877(1969) 5.Yagura, T., Kozu, T., and Seno, T.Mouse DNA polymerase accompanied by a novel RNA polymerase activity: Purification and partial characterizationJ. Biochem.91(2)607-618(1982) 6.Li, Y., Mitaxov, V., and Waksman, G.Structure-based design of Taq DNA polymerases with improved properties of dideoxynucleotide incorporationProc. Natl. Acad. Sci. USA96(17)9491-9496(1999) 7.Jarvis, M.F., Bianchi, B., Uchic, J.T., et al.[3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptorsJ. Pharmacol. Exp. Ther.310(1)407-416(2004)
Cas No. | SDF | Download SDF | |
别名 | ddATP | ||
Canonical SMILES | O=P(OP(OP(O)(O)=O)(O)=O)(O)OC[C@@H]1CC[C@H](N2C=NC3=C2N=CN=C3N)O1.[Li] | ||
分子式 | C10H16N5O11P3 ? XLi | 分子量 | 475.2 |
溶解度 | Water: soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1044 mL | 10.5219 mL | 21.0438 mL |
5 mM | 0.4209 mL | 2.1044 mL | 4.2088 mL |
10 mM | 0.2104 mL | 1.0522 mL | 2.1044 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。